AGEN AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
AGEN Current Performance
9.97%
Agenus incorporation
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to AGEN
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
WINT | Windtree therapeutics inc | 2 | 5 | 4 | 1 | 1 | |
CGEM | Cullinan therapeutics inc | 2 | 4 | 5 | 3 | 1 | |
PRE | Prenetics global ltd | - | 3 | 3 | 1 | 1 | |
BDRX | Biodexa pharmaceuticals plc | 3 | 2 | 2 | 1 | 1 | |
CGON | Cg oncology inc | - | 3 | 2 | 3 | 1 |
- WINT Windtree therapeutics incValue 2Trend 5Swing Trading 4Whale Interest 1Dividend 1See more
AGEN Profile
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.